Program

Keynote Addresses

7:10 p.m.-9:00 p.m.

Wrestling with melanoma
David Baltimore, California Institute of Technology, Pasadena, CA

Malignant progression and the formation of cancer stem cells
Robert A. Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, MA

Networking Reception

9:00 p.m.-10:30 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: Premalignant Lesions and Prevention

Chairperson: Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA
8:00 a.m.-10:00 a.m.

TGF-β: A master regulator of the tumor microenvironment
Harold L. Moses, Vanderbilt-Ingram Cancer Center, Nashville, TN

Conditions for successful immunotherapy of established lesions caused by high-risk Human Papilloma Virus
Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

Immunoprevention based on tumor-associated antigens
Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA

Global approach to tumor immunity: Network signatures of progression and survival*
Trevor Clancy, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

Restoration of tumor immune surveillance via selective stimulation of DLL1-Notch signaling*
Yuhui Huang, Vanderbilt University, Nashville, TN

Break

10:00 a.m.-10:30 a.m.

Session 2: Antibodies in Cancer Immunity

Chairperson: Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
10:30 a.m.-12:30 p.m.

Monoclonal antibody immunotherapy
Louis M. Weiner

Antibody fusions with interferon for the treatment of malignancy
Sherie L. Morrison, University of California, Los Angeles, CA

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells*
Tracy R. Daniels, University of California, Los Angeles, CA

Optimization of monoclonal antibodies for antitumor efficacy*
Yong Tang, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

B lymphocytes inhibit antitumor response in a murine EMT-6 tumor model by facilitating expansion of T-regulatory cells*
Yu Zhang, University of Miami Miller School of Medicine, Miami, FL

Free time / Lunch on own

12:30 p.m.-2:30 p.m.

Session 3: Workshop

Chairperson: Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2:30 p.m.-4:35 p.m.

Characterization of novel huCD16a (FcγRIIIA) transgenic mouse for preclinical assessment of therapeutic ADCC-mediating antibodies*
Christian A. Gerdes, Roche Glycart AG, Zurich, Switzerland

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants*
Karen M. Kaluza, Mayo Clinic, Rochester, MN

SHP2 regulates pSTAT1-mediated APM component expression and CTL recognition of head and neck cancer cells*
Michael S. Leibowitz, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Deletion of TGF-β receptor promotes mammary carcinoma progression by enhanced Th17 response*
Sergey Novitskiy, Vanderbilt-Ingram Cancer Center, Nashville, TN

Regulatory T cells are dependent on PI3K pathway allowing for their selective inhibition in vivo*
Raed N. Samara, National Cancer Institute, Bethesda, MD

The identification of two functionally distinct subsets (Treg and Teff) within the human CD4+CD39+ T cell population*
Patrick J. Schuler, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Galectin-1 modulates tolerance in neuroblastoma*
Rocío Soldati, Otto-von-Guericke University, Magdeburg, Germany

Poster Session A / Reception

4:35 p.m.-6:30 p.m.

Evening off / Dinner on own

6:30 p.m.-

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 4: Combined Therapy

Chairperson: Elizabeth M. Jaffee, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
8:00 a.m.-10:00 a.m.

Functional heterogeneity in CD8+ T cell memory subsets: Implications for immunotherapy
Stanley Riddell, Fred Hutchison Cancer Research Center, Seattle, WA

Curing metastatic colon tumors with combined vaccination, radiation, and hematopoietic cell transplantation
Samuel Strober, Stanford School of Medicine, Stanford, CA

Regulatory T cells and their role in the tumor microenvironment
Elizabeth M. Jaffee

Vaccination with lymphoma cells secreting gp96-Ig leads to the generation and expansion of CD8 effector cells in autologous HSCT recipients and is enhanced by IL-2 antibody-cytokine complex*
Robert G. Newman, University of Miami, Miami, FL

An uncontrolled phase II study of the P53-SLP® vaccine combined with low-dose cyclophosphamide for epithelial ovarian cancer*
Hans Nijman, University Medical Center Groningen, Groningen, The Netherlands

Break

10:00 a.m.-10:30 a.m.

Session 5: Epigenetic Regulation of Tumor Growth and Immune Recognition

Chairperson: Eduardo M. Sotomayor, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
10:30 a.m.-12:30 p.m.

Targeting specific histone deacetylases in immune cells and tumor cells to overcome tumor-induced tolerance
Eduardo M. Sotomayor

Selective depletion of Foxp3⁺ regulatory T cells improves effective therapeutic vaccination against established melanoma
Jochen Huehn, Helmholtz Centre for Infection Research, Braunschweig, Germany

Epigenetic targeting of Foxp3⁺ Tregs to enhance antitumor immunity
Wayne W. Hancock, University of Pennsylvania, Philadelphia, PA

MUC1 regulates interleukins expression in cancer cells*
Sandra Cascio, University of Pittsburgh, Pittsburgh, PA

ATF3, a hub of the stress-response network, promotes a systemic host environment that enhances cancer metastasis*
Tsonwin Hai, Ohio State University, Columbus, OH

Poster Session B / Lunch

12:30 p.m.-2:30 p.m.

Session 6: New Advances in the Development of Cancer Vaccines

Chairperson: Esteban Celis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2:30 p.m.-4:30 p.m.

Reprogramming the immune environment in cancer via dendritic cells
Anna Karolina Palucka, Baylor University Medical Center, Dallas, TX

Polarized dendritic cells in cancer therapy: Getting dendritic cells to lymph nodes and effector T cells to tumors
Pawel Kalinski, University of Pittsburgh, Pittsburgh, PA

Overcoming obstacles for the development of potent and effective peptide vaccines
Esteban Celis

Dual roles of CD91 in heat shock protein-mediated antitumor immunity*
Robert J. Binder, University of Pittsburgh, Pittsburgh, PA

Higher avidity mesothelin-specific CD8+ T cell repertoires are associated with longer disease-free survival and tumor-trafficking in patients treated with a GM-CSF-secreting pancreatic tumor vaccine*
Eric R. Lutz, Johns Hopkins University School of Medicine, Baltimore, MD

Evening off / Dinner on own

4:30 p.m.-

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: Regulation of Immune Responses in Cancer: A Translational Paradigm

Chairperson: Theresa L. Whiteside, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA
8:00 a.m.-10:00 a.m.

Human regulatory T cells (Treg) utilize adenosine and PGE₂ to mediate immune suppression
Theresa L. Whiteside

Immune monitoring of CTLA-4 blockade on a presurgical clinical trial: Implicating the ICOS/ICOSL pathway in antitumor immune responses
Padmanee Sharma, University of Texas MD Anderson Cancer Center, Houston, TX

Blocking PD-1 in advanced cancer
Charles G. Drake, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Molecular characterization of tumor-associated neutrophils*
Zvi G. Fridlender, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

NY-ESO-1-specific CD8 T-cell response in NY-ESO-1 seropositive metastatic melanoma patients treated with ipilimumab correlates with clinical benefit*
Jianda Yuan, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY

Break

10:00 a.m.-10:30 a.m.

Session 8: Harnessing the Immune System to Prevent and Fight Disease

Chairperson: Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands
10:30 a.m.-12:30 p.m.

Next-generation preventive HPV vaccines
Richard B. Roden, Johns Hopkins University, Baltimore, MD

Inflammatory cytokines and autocrine tumor-promoting networks
Frances R. Balkwill, Centre for Cancer and Inflammation, Barts and the London School of Medicine and Dentistry, London, United Kingdom

Marrow-infiltrating lymphocytes: Role in disease and therapy
Ivan Borrello, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Th-1 lymphocytes promote dendritic cell tumoricidal activity*
Collin J. LaCasse, University of Arizona, Tucson, AZ

A new type I NKT cell agonist induces tumor immunity through an unconventional pathway*
Masaki Terabe, National Cancer Institute, Bethesda, MD

Closing Remarks / Departure

12:30 p.m.-12:45 p.m.